AXA Framlington Biotech Fund - R IncomeRegister to Unlock Ratings |
Performance History | 30/09/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 31.4 | 2.3 | 3.0 | 1.1 | 3.8 | |
+/-Cat | 5.5 | 11.4 | 10.9 | 2.4 | 5.1 | |
+/-B’mrk | -1.5 | 2.0 | 0.6 | -6.2 | -2.9 | |
Category: Sector Equity Biotechnology | ||||||
Category Benchmark: Morningstar Gbl Biotechnolo... |
Key Stats | ||
NAV 04/10/2024 | GBX 269.40 | |
Day Change | -1.89% | |
Morningstar Category™ | Sector Equity Biotechnology | |
IA (formerly IMA) Sector | Specialist | |
ISIN | GB0031007254 | |
Fund Size (Mil) 30/08/2024 | GBP 432.07 | |
Share Class Size (Mil) 04/10/2024 | GBP 23.96 | |
Max Initial Charge | - | |
Ongoing Charge 01/06/2024 | 1.56% |
Investment Objective: AXA Framlington Biotech Fund - R Income |
The aim of this Fund is to provide long-term capital growth over a period of 5 years or more. The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Manager selects shares based upon analysis of a company’s financial status, quality of its management, expected profitability and prospects for growth. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Chris Eccles 29/03/2024 | ||
Cinney Zhang 29/03/2024 | ||
Click here to see others | ||
Inception Date 26/11/2001 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology TR USD | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for AXA Framlington Biotech Fund - R Income | 31/08/2024 |
|
|
Top 5 Holdings | Sector | % |
Regeneron Pharmaceuticals Inc | Healthcare | 9.07 |
Vertex Pharmaceuticals Inc | Healthcare | 7.81 |
Amgen Inc | Healthcare | 6.59 |
AstraZeneca PLC ADR | Healthcare | 5.33 |
Alnylam Pharmaceuticals Inc | Healthcare | 3.85 |
Increase Decrease New since last portfolio | ||
AXA Framlington Biotech Fund - R Income |